commonly prescribed diagnostic tests and to know its effect on their prescribing preferences. METHODS: This study is a descriptive cross-sectional survey which includes data gathering through questionnaire, retrieval, tabulating, and interpreting of results a probability stratified random sampling of 125 TMC physicians (regular consultants, fellows, and residents) was done. The sample size was computed using the Lynche formula. The physicians were stratified by specialties which include Internal Medicine, Surgery, Pediatrics, Obstetrics and Gynecology, Ophthalmology, and ENT-Head and Neck Surgery and were asked to answer a pre-tested questionnaire. Non-respondents were sent another questionnaire for them to answer to increase response rate. The collected data were analyzed using the percentage and weighted average and one-way analysis of variance. Inferential analysis was done using ANOVA. SPSS software was used for these purposes. RESULTS: Verbal interpretation of the descriptive statistics shows that all respondent physicians agree to the statement that the prices of medications and diagnostic tests are important factors which influence them in their practice. Furthermore, the respondent physicians believe that physicians should know the prices of medications and tests they prescribe or order. They also consider the economic status of their patients in their practice. However, descriptive data based on the mean price estimates from all specialties, whether residents, fellows, or consultants, show significant difference in the physician perceived prices of commonly prescribed and ordered medications and diagnostic tests and the actual TMC prices of such medications and tests (p value >0.05) thereby rejecting the null hypothesis saying otherwise. CONCLUSION: The Medical City physician is not aware of the prices of medications and diagnostic tests he commonly prescribes or orders.
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PMC5 ARE NON-INFERIORITY TRIALS SUITABLE FOR ECONOMIC EVALUATION? ESTIMATION IS STILL MORE IMPORTANT THAN HYPOTHESIS TESTING
Briggs A 1 , Backhouse M 2 1 University of Glasgow, Glasgow, UK, 2 Novartis Pharmaceuticals, Basel, Switzerland OBJECTIVES: The use of cost-minimisation analysis, based on a negative result from a clinical trial, has recently been questioned. Instead, it has been argued that cost-minimisation analysis should only be undertaken as part of an equivalence trial, designed to confirm the absence of a meaningful difference between treatments. The "non-inferiority" trial is becoming a popular method of comparing a new treatment to an existing standard as non-inferiority may be an acceptable outcome for licensing purposes. Non-inferiority trials are designed to show that a new treatment is no less effective than an existing treatment-in reality, it may be more effective or have a similar effect (within a margin of clinical equivalence). METHODS: In this paper, the role of the non-inferiority trial design is critically appraised as a vehicle for economic evaluation. RESULTS: A number of issues are noted in relation to non-inferiority designs that limit their usefulness for making judgements concerning the value for money of treatments. The margin of clinical equivalence is essentially arbitrary and is rendered meaningless once costs (both in terms of resources and the health effects of any adverse events) are considered. From an economic perspective, acceptance of a new treatment can only be recommended if the new treatment is both "non-inferior" in both clinical and cost terms, however, the role of the margin of clinical equivalence (and potentially a similar margin of cost equivalence) serves to cloud the comparison with the traditional concept of "dominance" in economic studies. CONCLUSION: The design of trial in terms of "superiority" or "non-inferiority" does not change the fact that separate and sequential tests of hypothesis for costs and effects independently are to be avoided in economic evaluation. The recommendation remains that estimation and not hypothesis testing should be the key to interpreting costeffectiveness studies of new treatments. 
